http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 07 Jan 2026 12:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Press+Releases/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html <p align="justify"><b>Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026</b> - <b>GENFIT (Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.</p> <p align="justify"><b>2026 Financial Calendar</b></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">February 26, 2026</td><td style="width:25%;;text-align: justify ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; http://www.streetinsider.com/Globe+Newswire/GENFIT+Announces+2026+Financial+Calendar/25819067.html Wed, 07 Jan 2026 12:00:00 -0500 A.06822034 A.31066700 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.61461624 http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html <p>GENFIT (Euronext: GNFT) announced that its investigational drug candidate G1090N demonstrated a favorable safety profile in Phase 1 testing and showed anti-inflammatory activity in laboratory studies. The company is developing the treatment for Acute-On-Chronic Liver Failure, a condition with no approved therapies.</p> <p>The Phase 1 trial enrolled 76 healthy volunteers across two segments testing single and multiple ascending doses. GENFIT reported that G1090N's safety profile supports continued clinical evaluation.</p> <p>In separate laboratory studies using blood samples, G1090N showed up to 76% inhibition of inflammatory cytokines IL-6 and TNFα production. The company tested the drug's bioactive metabolite on blood samples from patients with http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html Tue, 06 Jan 2026 12:12:27 -0500 A.06822034 A.31066700 A.41659699 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.37875165 O.61461624 http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html <p>GENFIT (Euronext: GNFT) announced that its investigational drug candidate G1090N demonstrated a favorable safety profile in Phase 1 testing and showed anti-inflammatory activity in laboratory studies. The company is developing the treatment for Acute-On-Chronic Liver Failure, a condition with no approved therapies.</p> <p>The Phase 1 trial enrolled 76 healthy volunteers across two segments testing single and multiple ascending doses. GENFIT reported that G1090N's safety profile supports continued clinical evaluation.</p> <p>In separate laboratory studies using blood samples, G1090N showed up to 76% inhibition of inflammatory cytokines IL-6 and TNFα production. The company tested the drug's bioactive metabolite on blood samples from patients with http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html Tue, 06 Jan 2026 12:12:27 -0500 A.06822034 A.31066700 A.41659699 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.37875165 O.61461624 http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html <p>GENFIT (Euronext: GNFT) announced that its investigational drug candidate G1090N demonstrated a favorable safety profile in Phase 1 testing and showed anti-inflammatory activity in laboratory studies. The company is developing the treatment for Acute-On-Chronic Liver Failure, a condition with no approved therapies.</p> <p>The Phase 1 trial enrolled 76 healthy volunteers across two segments testing single and multiple ascending doses. GENFIT reported that G1090N's safety profile supports continued clinical evaluation.</p> <p>In separate laboratory studies using blood samples, G1090N showed up to 76% inhibition of inflammatory cytokines IL-6 and TNFα production. The company tested the drug's bioactive metabolite on blood samples from patients with http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html Tue, 06 Jan 2026 12:12:27 -0500 A.06822034 A.31066700 A.41659699 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.37875165 O.61461624 http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html <p>GENFIT (Euronext: GNFT) announced that its investigational drug candidate G1090N demonstrated a favorable safety profile in Phase 1 testing and showed anti-inflammatory activity in laboratory studies. The company is developing the treatment for Acute-On-Chronic Liver Failure, a condition with no approved therapies.</p> <p>The Phase 1 trial enrolled 76 healthy volunteers across two segments testing single and multiple ascending doses. GENFIT reported that G1090N's safety profile supports continued clinical evaluation.</p> <p>In separate laboratory studies using blood samples, G1090N showed up to 76% inhibition of inflammatory cytokines IL-6 and TNFα production. The company tested the drug's bioactive metabolite on blood samples from patients with http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html Tue, 06 Jan 2026 12:12:27 -0500 A.06822034 A.31066700 A.41659699 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.37875165 O.61461624 http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html <p>GENFIT (Euronext: GNFT) announced that its investigational drug candidate G1090N demonstrated a favorable safety profile in Phase 1 testing and showed anti-inflammatory activity in laboratory studies. The company is developing the treatment for Acute-On-Chronic Liver Failure, a condition with no approved therapies.</p> <p>The Phase 1 trial enrolled 76 healthy volunteers across two segments testing single and multiple ascending doses. GENFIT reported that G1090N's safety profile supports continued clinical evaluation.</p> <p>In separate laboratory studies using blood samples, G1090N showed up to 76% inhibition of inflammatory cytokines IL-6 and TNFα production. The company tested the drug's bioactive metabolite on blood samples from patients with http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html Tue, 06 Jan 2026 12:12:27 -0500 A.06822034 A.31066700 A.41659699 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.37875165 O.61461624 http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html <p>GENFIT (Euronext: GNFT) announced that its investigational drug candidate G1090N demonstrated a favorable safety profile in Phase 1 testing and showed anti-inflammatory activity in laboratory studies. The company is developing the treatment for Acute-On-Chronic Liver Failure, a condition with no approved therapies.</p> <p>The Phase 1 trial enrolled 76 healthy volunteers across two segments testing single and multiple ascending doses. GENFIT reported that G1090N's safety profile supports continued clinical evaluation.</p> <p>In separate laboratory studies using blood samples, G1090N showed up to 76% inhibition of inflammatory cytokines IL-6 and TNFα production. The company tested the drug's bioactive metabolite on blood samples from patients with http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html Tue, 06 Jan 2026 12:12:27 -0500 A.06822034 A.31066700 A.41659699 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.37875165 O.61461624 http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html <p>GENFIT (Euronext: GNFT) announced that its investigational drug candidate G1090N demonstrated a favorable safety profile in Phase 1 testing and showed anti-inflammatory activity in laboratory studies. The company is developing the treatment for Acute-On-Chronic Liver Failure, a condition with no approved therapies.</p> <p>The Phase 1 trial enrolled 76 healthy volunteers across two segments testing single and multiple ascending doses. GENFIT reported that G1090N's safety profile supports continued clinical evaluation.</p> <p>In separate laboratory studies using blood samples, G1090N showed up to 76% inhibition of inflammatory cytokines IL-6 and TNFα production. The company tested the drug's bioactive metabolite on blood samples from patients with http://www.streetinsider.com/FDA/GENFIT+reports+positive+Phase+1+results+for+liver+disease+drug+G1090N/25811809.html Tue, 06 Jan 2026 12:12:27 -0500 A.06822034 A.31066700 A.41659699 A.50207282 A.50214025 GNFT O.00346648 O.00379991 O.20026344 O.37875165 O.61461624